Movement Alert｜Guardant Health Inc. Rises 5.39% in Regular Trading, Q2 Revenue Beat and Full-Year Guidance Raise Extend Post-Earnings Momentum

Market Focus08-07 21:57

On August 7, Guardant Health Inc. rose 5.39% in regular trading, trading near $165.98/share with turnover of $44.12 million, extending the upward trend following its recent earnings release.

The move continues to be driven by the company's strong Q2 results reported on July 30. Revenue came in at $335.0 million, up 44.3% year-over-year and significantly exceeding the analyst consensus estimate of $314.2 million. The company simultaneously raised its full-year revenue guidance to $1.34-$1.36 billion from a prior range of $1.30-$1.32 billion, well above the Street estimate of $1.31 billion. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier.

Analyst sentiment has strengthened alongside the results. RBC Capital Markets raised its price target to $200 from $185 while maintaining an Outperform rating. The stock carries a consensus Buy rating with a mean price target of $191.09. Recent catalysts including multiple FDA approvals for Guardant360 CDx and Shield blood test inclusion in American Cancer Society guidelines have further reinforced the bullish thesis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126249907?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126249907","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Inc. Rises 5.39% in Regular Trading, Q2 Revenue Beat and Full-Year Guidance Raise Extend Post-Earnings Momentum","media":"Market Focus","content":"<p><p>On August 7, Guardant Health Inc. rose 5.39% in regular trading, trading near $165.98/share with turnover of $44.12 million, extending the upward trend following its recent earnings release.</p><p>The move continues to be driven by the company's strong Q2 results reported on July 30. Revenue came in at $335.0 million, up 44.3% year-over-year and significantly exceeding the analyst consensus estimate of $314.2 million. The company simultaneously raised its full-year revenue guidance to $1.34-$1.36 billion from a prior range of $1.30-$1.32 billion, well above the Street estimate of $1.31 billion. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier.</p><p>Analyst sentiment has strengthened alongside the results. RBC Capital Markets raised its price target to $200 from $185 while maintaining an Outperform rating. The stock carries a consensus Buy rating with a mean price target of $191.09. Recent catalysts including multiple FDA approvals for Guardant360 CDx and Shield blood test inclusion in American Cancer Society guidelines have further reinforced the bullish thesis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Inc. Rises 5.39% in Regular Trading, Q2 Revenue Beat and Full-Year Guidance Raise Extend Post-Earnings Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Inc. Rises 5.39% in Regular Trading, Q2 Revenue Beat and Full-Year Guidance Raise Extend Post-Earnings Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Guardant Health Inc. rose 5.39% in regular trading, trading near $165.98/share with turnover of $44.12 million, extending the upward trend following its recent earnings release.</p><p>The move continues to be driven by the company's strong Q2 results reported on July 30. Revenue came in at $335.0 million, up 44.3% year-over-year and significantly exceeding the analyst consensus estimate of $314.2 million. The company simultaneously raised its full-year revenue guidance to $1.34-$1.36 billion from a prior range of $1.30-$1.32 billion, well above the Street estimate of $1.31 billion. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier.</p><p>Analyst sentiment has strengthened alongside the results. RBC Capital Markets raised its price target to $200 from $185 while maintaining an Outperform rating. The stock carries a consensus Buy rating with a mean price target of $191.09. Recent catalysts including multiple FDA approvals for Guardant360 CDx and Shield blood test inclusion in American Cancer Society guidelines have further reinforced the bullish thesis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1126249907","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126249907","pubTimestamp":1786111032,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Guardant Health Inc. rose 5.39% in regular trading, trading near $165.98/share with turnover of $44.12 million, extending the upward trend following its recent earnings release.The move...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"走势警报|Guardant Health Inc. 常规交易中上涨 5.39%，第二季度收入超出预期，全年指引上调延续了财报后的势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On August 7, Guardant Health Inc. rose 5.39% in regular trading, trading near $165.98/share with turnover of $44.12 million, extending the upward trend following its recent earnings release.The move continues to be driven by the company's strong Q2 results reported on July 30. Revenue came in at $335.0 million, up 44.3% year-over-year and significantly exceeding the analyst consensus estimate of $314.2 million. The company simultaneously raised its full-year revenue guidance to $1.34-$1.36 billion from a prior range of $1.30-$1.32 billion, well above the Street estimate of $1.31 billion. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier.Analyst sentiment has strengthened alongside the results. RBC Capital Markets raised its price target to $200 from $185 while maintaining an Outperform rating. The stock carries a consensus Buy rating with a mean price target of $191.09. Recent catalysts including multiple FDA approvals for Guardant360 CDx and Shield blood test inclusion in American Cancer Society guidelines have further reinforced the bullish thesis.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126249907","isCrawlerRequest":true}